VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- September 29, 2006 -- Protiva Biotherapeutics Inc. announced today that, based on pre-clinical studies involving several cancer models, including models of human cancer, its Stable Nucleic-Acid Lipid Particle (SNALP) technology demonstrated strong efficacy in the selective elimination of malignant tumor cells, while sparing normal healthy cells in the same tissue. In pre-clinical studies against three cancer causing target genes, Protiva's SNALP technology successfully silenced the targeted genes in the tumor cells, stopping tumor cell growth.
